MGMT and glioblastoma: Kaplan–Meier survival analyses revealed that PsP patients had significantly prolonged overall survival (21.3 ± 4.3 vs. 18.3 ± 1.1 months, log-rank P = .043) than TP patients (Figure 5). When survival analyses were performed using MGMT promoter methylation status as an independent variable, MGMT methylated GBM patients had significantly longer survival than those with unmethylated MGMT promoter (23.4 ± 2.6 vs. 17.9 ± 0.6 months, log-rank P = .015).